| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 30 | 2024 | 91 | 7.720 |
Why?
|
| Macular Edema | 28 | 2023 | 50 | 7.400 |
Why?
|
| Macular Degeneration | 24 | 2024 | 61 | 4.970 |
Why?
|
| Retinal Diseases | 20 | 2022 | 90 | 4.640 |
Why?
|
| Angiogenesis Inhibitors | 22 | 2024 | 293 | 4.300 |
Why?
|
| Vitreous Body | 23 | 2019 | 54 | 3.550 |
Why?
|
| Tomography, Optical Coherence | 28 | 2023 | 136 | 3.340 |
Why?
|
| Vitrectomy | 21 | 2021 | 52 | 3.140 |
Why?
|
| Visual Acuity | 30 | 2024 | 199 | 2.970 |
Why?
|
| Retina | 18 | 2023 | 220 | 2.660 |
Why?
|
| Wet Macular Degeneration | 8 | 2024 | 25 | 2.140 |
Why?
|
| Fluorescein Angiography | 18 | 2023 | 96 | 2.090 |
Why?
|
| Ophthalmology | 9 | 2023 | 44 | 2.060 |
Why?
|
| Uveitis | 7 | 2024 | 31 | 1.940 |
Why?
|
| Vascular Endothelial Growth Factor A | 13 | 2024 | 405 | 1.940 |
Why?
|
| Laser Coagulation | 9 | 2021 | 55 | 1.790 |
Why?
|
| Sclera | 5 | 2021 | 11 | 1.700 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2023 | 563 | 1.700 |
Why?
|
| Vitreoretinal Surgery | 6 | 2022 | 8 | 1.620 |
Why?
|
| Aqueous Humor | 9 | 2008 | 24 | 1.580 |
Why?
|
| Macula Lutea | 4 | 2020 | 19 | 1.550 |
Why?
|
| Retinal Detachment | 9 | 2021 | 66 | 1.510 |
Why?
|
| Endophthalmitis | 8 | 2022 | 22 | 1.420 |
Why?
|
| Retinal Perforations | 6 | 2020 | 19 | 1.410 |
Why?
|
| Antifungal Agents | 8 | 2010 | 122 | 1.360 |
Why?
|
| Intravitreal Injections | 18 | 2023 | 73 | 1.330 |
Why?
|
| Eye Diseases | 4 | 2021 | 58 | 1.300 |
Why?
|
| Central Serous Chorioretinopathy | 2 | 2022 | 3 | 1.290 |
Why?
|
| Choroidal Neovascularization | 10 | 2018 | 33 | 1.280 |
Why?
|
| Intraocular Pressure | 10 | 2020 | 57 | 1.270 |
Why?
|
| Humans | 148 | 2024 | 89567 | 1.270 |
Why?
|
| Geographic Atrophy | 6 | 2024 | 12 | 1.230 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 8 | 2023 | 67 | 1.230 |
Why?
|
| Metformin | 6 | 2024 | 124 | 1.180 |
Why?
|
| Cataract Extraction | 6 | 2021 | 33 | 1.160 |
Why?
|
| Triazoles | 8 | 2010 | 104 | 1.120 |
Why?
|
| Anti-Bacterial Agents | 7 | 2019 | 794 | 1.040 |
Why?
|
| Choroid Diseases | 3 | 2022 | 5 | 1.030 |
Why?
|
| Aza Compounds | 4 | 2006 | 8 | 1.000 |
Why?
|
| Pyrimidines | 8 | 2010 | 370 | 0.960 |
Why?
|
| Diabetes Mellitus | 9 | 2024 | 743 | 0.960 |
Why?
|
| Quinolines | 4 | 2006 | 86 | 0.950 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2018 | 950 | 0.920 |
Why?
|
| Ranibizumab | 9 | 2016 | 16 | 0.890 |
Why?
|
| Disease Management | 5 | 2018 | 326 | 0.890 |
Why?
|
| Eye Infections, Fungal | 6 | 2010 | 14 | 0.890 |
Why?
|
| Photochemotherapy | 4 | 2015 | 100 | 0.880 |
Why?
|
| Iatrogenic Disease | 1 | 2023 | 70 | 0.860 |
Why?
|
| Fluocinolone Acetonide | 3 | 2023 | 8 | 0.860 |
Why?
|
| Iris Diseases | 2 | 2015 | 6 | 0.850 |
Why?
|
| Eye Infections, Bacterial | 4 | 2024 | 16 | 0.830 |
Why?
|
| Choroid | 8 | 2022 | 36 | 0.750 |
Why?
|
| Sclerostomy | 2 | 2011 | 2 | 0.740 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 4 | 2018 | 16 | 0.690 |
Why?
|
| Glucocorticoids | 9 | 2023 | 357 | 0.690 |
Why?
|
| Retinal Vessels | 4 | 2022 | 59 | 0.670 |
Why?
|
| Microsurgery | 3 | 2017 | 90 | 0.670 |
Why?
|
| Fluoroquinolones | 6 | 2006 | 22 | 0.660 |
Why?
|
| Polyps | 2 | 2018 | 29 | 0.650 |
Why?
|
| Bevacizumab | 7 | 2019 | 268 | 0.650 |
Why?
|
| Microbial Sensitivity Tests | 9 | 2019 | 150 | 0.640 |
Why?
|
| Aged | 45 | 2024 | 19144 | 0.640 |
Why?
|
| Choroiditis | 2 | 2010 | 7 | 0.620 |
Why?
|
| Drug Implants | 7 | 2023 | 34 | 0.610 |
Why?
|
| Middle Aged | 43 | 2024 | 25996 | 0.600 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1131 | 0.580 |
Why?
|
| Retinal Vein Occlusion | 2 | 2014 | 8 | 0.560 |
Why?
|
| Lasers, Semiconductor | 1 | 2016 | 2 | 0.560 |
Why?
|
| Laser Therapy | 2 | 2020 | 148 | 0.550 |
Why?
|
| Peptides | 1 | 2020 | 649 | 0.550 |
Why?
|
| Light Coagulation | 2 | 2021 | 6 | 0.540 |
Why?
|
| Dexamethasone | 4 | 2019 | 342 | 0.540 |
Why?
|
| Male | 48 | 2024 | 42464 | 0.530 |
Why?
|
| Drug Delivery Systems | 4 | 2022 | 178 | 0.530 |
Why?
|
| Biological Availability | 9 | 2015 | 91 | 0.500 |
Why?
|
| Facility Design and Construction | 1 | 2015 | 5 | 0.500 |
Why?
|
| Administration, Oral | 8 | 2015 | 666 | 0.500 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2015 | 4 | 0.500 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 270 | 0.490 |
Why?
|
| Iris | 1 | 2015 | 5 | 0.490 |
Why?
|
| Vision Disorders | 3 | 2016 | 75 | 0.490 |
Why?
|
| Basement Membrane | 2 | 2019 | 55 | 0.490 |
Why?
|
| Professional Practice | 1 | 2015 | 46 | 0.490 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 59 | 0.480 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2015 | 25 | 0.480 |
Why?
|
| Fovea Centralis | 6 | 2021 | 21 | 0.480 |
Why?
|
| Fibrinolysin | 2 | 2019 | 26 | 0.470 |
Why?
|
| Physical Examination | 1 | 2015 | 149 | 0.470 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 253 | 0.460 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 6766 | 0.460 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2011 | 37 | 0.460 |
Why?
|
| Uveitis, Posterior | 1 | 2013 | 1 | 0.460 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 111 | 0.450 |
Why?
|
| Retrospective Studies | 18 | 2022 | 9112 | 0.450 |
Why?
|
| Female | 43 | 2024 | 46371 | 0.440 |
Why?
|
| Cornea | 3 | 2019 | 70 | 0.430 |
Why?
|
| Tissue Adhesions | 1 | 2013 | 50 | 0.420 |
Why?
|
| Propylene Glycols | 1 | 2013 | 30 | 0.420 |
Why?
|
| Eye Foreign Bodies | 1 | 2012 | 1 | 0.420 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2012 | 5 | 0.420 |
Why?
|
| Glass | 1 | 2012 | 15 | 0.410 |
Why?
|
| Suture Techniques | 2 | 2011 | 144 | 0.410 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 354 | 0.410 |
Why?
|
| Sphingosine | 1 | 2013 | 74 | 0.410 |
Why?
|
| Career Choice | 1 | 2014 | 148 | 0.410 |
Why?
|
| Chromatography, High Pressure Liquid | 9 | 2008 | 315 | 0.410 |
Why?
|
| Peptide Fragments | 2 | 2019 | 462 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 585 | 0.390 |
Why?
|
| Faculty, Medical | 1 | 2014 | 187 | 0.390 |
Why?
|
| Anti-Infective Agents | 2 | 2003 | 91 | 0.390 |
Why?
|
| Endoscopy | 1 | 2015 | 352 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1180 | 0.380 |
Why?
|
| Wound Healing | 2 | 2011 | 360 | 0.380 |
Why?
|
| Keratitis | 2 | 2019 | 22 | 0.380 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 31 | 0.370 |
Why?
|
| Tissue Adhesives | 1 | 2011 | 23 | 0.370 |
Why?
|
| Ischemia | 1 | 2013 | 252 | 0.370 |
Why?
|
| Prospective Studies | 16 | 2024 | 4309 | 0.370 |
Why?
|
| Voriconazole | 8 | 2010 | 18 | 0.370 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 217 | 0.370 |
Why?
|
| Coccidioides | 1 | 2010 | 5 | 0.360 |
Why?
|
| Fluconazole | 1 | 2010 | 11 | 0.360 |
Why?
|
| Coccidioidomycosis | 1 | 2010 | 7 | 0.360 |
Why?
|
| Bandages, Hydrocolloid | 1 | 2010 | 2 | 0.360 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 274 | 0.350 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 476 | 0.350 |
Why?
|
| Specialization | 3 | 2021 | 70 | 0.340 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 198 | 0.330 |
Why?
|
| Treatment Outcome | 12 | 2022 | 8209 | 0.330 |
Why?
|
| Retinal Artery Occlusion | 1 | 2009 | 12 | 0.330 |
Why?
|
| Cysts | 1 | 2010 | 106 | 0.330 |
Why?
|
| Foramen Ovale, Patent | 1 | 2009 | 18 | 0.330 |
Why?
|
| Aptamers, Nucleotide | 2 | 2006 | 23 | 0.330 |
Why?
|
| Glaucoma, Open-Angle | 4 | 2022 | 19 | 0.320 |
Why?
|
| Eye Infections | 2 | 2024 | 3 | 0.320 |
Why?
|
| Porphyrins | 2 | 2005 | 39 | 0.310 |
Why?
|
| Inpatients | 3 | 2016 | 311 | 0.310 |
Why?
|
| Photosensitizing Agents | 2 | 2005 | 51 | 0.310 |
Why?
|
| Phenylacetates | 1 | 2007 | 3 | 0.300 |
Why?
|
| Benzeneacetamides | 1 | 2007 | 11 | 0.300 |
Why?
|
| Drug Carriers | 2 | 2005 | 82 | 0.300 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 360 | 0.300 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 976 | 0.290 |
Why?
|
| Appointments and Schedules | 2 | 2019 | 54 | 0.280 |
Why?
|
| Collagen | 2 | 2005 | 294 | 0.280 |
Why?
|
| Cataract | 3 | 2021 | 86 | 0.270 |
Why?
|
| Genetic Therapy | 3 | 2018 | 371 | 0.270 |
Why?
|
| Indocyanine Green | 3 | 2015 | 22 | 0.260 |
Why?
|
| Prototheca | 1 | 2005 | 1 | 0.260 |
Why?
|
| Vision, Low | 2 | 2015 | 15 | 0.250 |
Why?
|
| Genetic Testing | 2 | 2021 | 539 | 0.250 |
Why?
|
| Retinal Photoreceptor Cell Inner Segment | 2 | 2017 | 4 | 0.250 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 3658 | 0.250 |
Why?
|
| Clinical Protocols | 2 | 2016 | 158 | 0.240 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 516 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2327 | 0.240 |
Why?
|
| Coloring Agents | 2 | 2015 | 65 | 0.240 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 782 | 0.240 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 327 | 0.240 |
Why?
|
| Injections | 8 | 2009 | 116 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 834 | 0.230 |
Why?
|
| Quality of Life | 3 | 2022 | 1671 | 0.230 |
Why?
|
| Diet, High-Fat | 2 | 2022 | 119 | 0.230 |
Why?
|
| Scleral Buckling | 2 | 2021 | 18 | 0.220 |
Why?
|
| Tonometry, Ocular | 3 | 2016 | 11 | 0.220 |
Why?
|
| Phacoemulsification | 2 | 2021 | 16 | 0.220 |
Why?
|
| Adult | 20 | 2021 | 26684 | 0.210 |
Why?
|
| Syphilis, Congenital | 1 | 2002 | 6 | 0.210 |
Why?
|
| Steroids | 3 | 2019 | 173 | 0.210 |
Why?
|
| Retinal Telangiectasis | 1 | 2022 | 5 | 0.210 |
Why?
|
| Chronic Disease | 2 | 2022 | 952 | 0.200 |
Why?
|
| Inflammation | 3 | 2023 | 975 | 0.190 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2021 | 5 | 0.190 |
Why?
|
| Insulin | 2 | 2024 | 1148 | 0.190 |
Why?
|
| Retinal Neovascularization | 1 | 2020 | 5 | 0.190 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2021 | 24 | 0.180 |
Why?
|
| Sulfonamides | 1 | 2023 | 318 | 0.180 |
Why?
|
| Half-Life | 1 | 2020 | 97 | 0.180 |
Why?
|
| Total Quality Management | 1 | 2020 | 33 | 0.180 |
Why?
|
| Administration, Topical | 4 | 2018 | 96 | 0.180 |
Why?
|
| Hemangioblastoma | 1 | 2020 | 13 | 0.170 |
Why?
|
| Integrins | 1 | 2020 | 78 | 0.170 |
Why?
|
| Choroid Hemorrhage | 1 | 2019 | 2 | 0.170 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2020 | 17 | 0.170 |
Why?
|
| Angiography | 2 | 2020 | 208 | 0.170 |
Why?
|
| Medicare | 4 | 2024 | 426 | 0.170 |
Why?
|
| Universities | 1 | 2021 | 145 | 0.170 |
Why?
|
| Micrococcaceae | 1 | 2019 | 3 | 0.170 |
Why?
|
| Ergonomics | 1 | 2019 | 22 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2016 | 1708 | 0.170 |
Why?
|
| Ocular Hypertension | 1 | 2019 | 8 | 0.160 |
Why?
|
| United States | 7 | 2024 | 7041 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 51 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1862 | 0.160 |
Why?
|
| Machine Learning | 1 | 2021 | 263 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2020 | 102 | 0.160 |
Why?
|
| Retinal Dystrophies | 1 | 2018 | 1 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 435 | 0.160 |
Why?
|
| Time Factors | 5 | 2019 | 5333 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2019 | 92 | 0.150 |
Why?
|
| Fungemia | 2 | 2010 | 15 | 0.150 |
Why?
|
| Vitreous Detachment | 1 | 2017 | 3 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 164 | 0.140 |
Why?
|
| Functional Laterality | 2 | 2010 | 200 | 0.140 |
Why?
|
| Ophthalmic Solutions | 3 | 2005 | 17 | 0.140 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2017 | 66 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 271 | 0.140 |
Why?
|
| Drug Approval | 2 | 2018 | 65 | 0.140 |
Why?
|
| Depression | 1 | 2021 | 510 | 0.140 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 135 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 276 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 38 | 0.140 |
Why?
|
| Protein Binding | 1 | 2020 | 1491 | 0.130 |
Why?
|
| Subretinal Fluid | 1 | 2016 | 2 | 0.130 |
Why?
|
| Accidental Falls | 1 | 2016 | 48 | 0.130 |
Why?
|
| Bacteria | 2 | 2015 | 481 | 0.130 |
Why?
|
| Drug Administration Routes | 1 | 2015 | 19 | 0.130 |
Why?
|
| Retinal Degeneration | 1 | 2016 | 29 | 0.130 |
Why?
|
| Optic Nerve | 3 | 2001 | 36 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2022 | 145 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2020 | 2878 | 0.130 |
Why?
|
| Animals | 9 | 2022 | 27476 | 0.130 |
Why?
|
| Eye Pain | 1 | 2015 | 4 | 0.130 |
Why?
|
| Anterior Eye Segment | 1 | 2015 | 6 | 0.130 |
Why?
|
| Ophthalmoscopy | 1 | 2015 | 14 | 0.130 |
Why?
|
| Therapeutic Equivalency | 1 | 2015 | 16 | 0.120 |
Why?
|
| Eyeglasses | 1 | 2015 | 8 | 0.120 |
Why?
|
| Planning Techniques | 1 | 2015 | 10 | 0.120 |
Why?
|
| Health Literacy | 1 | 2016 | 73 | 0.120 |
Why?
|
| Triamcinolone Acetonide | 2 | 2022 | 8 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 77 | 0.120 |
Why?
|
| Young Adult | 5 | 2021 | 6362 | 0.120 |
Why?
|
| Epiretinal Membrane | 1 | 2014 | 2 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2641 | 0.120 |
Why?
|
| Vitreous Hemorrhage | 2 | 2011 | 11 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2022 | 428 | 0.110 |
Why?
|
| Low-Level Light Therapy | 1 | 2013 | 15 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2013 | 26 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 111 | 0.110 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2013 | 30 | 0.110 |
Why?
|
| Accidents, Occupational | 1 | 2012 | 8 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 353 | 0.100 |
Why?
|
| Fourier Analysis | 2 | 2010 | 128 | 0.100 |
Why?
|
| Retinal Photoreceptor Cell Outer Segment | 1 | 2012 | 3 | 0.100 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2014 | 135 | 0.100 |
Why?
|
| Chorioretinitis | 1 | 2012 | 10 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2016 | 2296 | 0.100 |
Why?
|
| Fundus Oculi | 3 | 2018 | 33 | 0.100 |
Why?
|
| West Nile Fever | 1 | 2012 | 22 | 0.100 |
Why?
|
| Risk Factors | 5 | 2024 | 5523 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2012 | 207 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2016 | 402 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1723 | 0.100 |
Why?
|
| Glaucoma | 2 | 2012 | 33 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 384 | 0.090 |
Why?
|
| Electronic Health Records | 1 | 2015 | 350 | 0.090 |
Why?
|
| Retinal Hemorrhage | 1 | 2010 | 8 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1050 | 0.090 |
Why?
|
| Equipment Contamination | 1 | 2010 | 23 | 0.090 |
Why?
|
| Needles | 1 | 2010 | 40 | 0.090 |
Why?
|
| Ink | 1 | 2010 | 4 | 0.090 |
Why?
|
| Ophthalmologists | 2 | 2020 | 5 | 0.090 |
Why?
|
| Mass Screening | 1 | 2015 | 644 | 0.090 |
Why?
|
| Preoperative Care | 3 | 2014 | 395 | 0.090 |
Why?
|
| Eye Proteins | 1 | 2011 | 128 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2763 | 0.090 |
Why?
|
| Carbon | 1 | 2010 | 90 | 0.090 |
Why?
|
| Polymers | 1 | 2011 | 195 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1705 | 0.080 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2022 | 13 | 0.080 |
Why?
|
| Observer Variation | 1 | 2010 | 613 | 0.080 |
Why?
|
| Anterior Chamber | 1 | 2008 | 9 | 0.080 |
Why?
|
| Lenses, Intraocular | 1 | 2007 | 12 | 0.080 |
Why?
|
| Catheterization | 1 | 2009 | 237 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2011 | 1074 | 0.070 |
Why?
|
| Electroretinography | 2 | 2004 | 77 | 0.070 |
Why?
|
| Osmolar Concentration | 2 | 2004 | 182 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2018 | 182 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2007 | 103 | 0.070 |
Why?
|
| Transcriptome | 2 | 2022 | 654 | 0.070 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2006 | 13 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2018 | 312 | 0.070 |
Why?
|
| Mupirocin | 1 | 2006 | 6 | 0.070 |
Why?
|
| Conjunctiva | 1 | 2006 | 19 | 0.070 |
Why?
|
| Gram-Positive Bacteria | 1 | 2006 | 18 | 0.070 |
Why?
|
| Biodegradation, Environmental | 1 | 2005 | 18 | 0.060 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2005 | 5 | 0.060 |
Why?
|
| Psychometrics | 1 | 2007 | 330 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 34 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2005 | 87 | 0.060 |
Why?
|
| Blood | 1 | 2005 | 69 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1394 | 0.060 |
Why?
|
| Adolescent | 4 | 2018 | 9299 | 0.060 |
Why?
|
| Nasal Mucosa | 1 | 2006 | 191 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2005 | 123 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 44 | 0.060 |
Why?
|
| Histoplasmosis | 1 | 2005 | 26 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2005 | 296 | 0.060 |
Why?
|
| Candidiasis | 1 | 2005 | 37 | 0.060 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 198 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1928 | 0.060 |
Why?
|
| Tablets | 1 | 2006 | 122 | 0.060 |
Why?
|
| Methyldopa | 1 | 2024 | 3 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1762 | 0.060 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 72 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 65 | 0.060 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 69 | 0.060 |
Why?
|
| Fungi | 1 | 2004 | 66 | 0.050 |
Why?
|
| Atrophy | 1 | 2023 | 122 | 0.050 |
Why?
|
| Complement Inactivating Agents | 1 | 2023 | 4 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2023 | 55 | 0.050 |
Why?
|
| Biological Transport | 1 | 2004 | 401 | 0.050 |
Why?
|
| Microbiological Techniques | 1 | 2022 | 24 | 0.050 |
Why?
|
| Laser-Doppler Flowmetry | 5 | 2001 | 20 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2005 | 870 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 865 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 565 | 0.050 |
Why?
|
| Incidence | 2 | 2020 | 1598 | 0.050 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2021 | 23 | 0.050 |
Why?
|
| Blood Flow Velocity | 5 | 2001 | 200 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2022 | 46 | 0.050 |
Why?
|
| Capillaries | 1 | 2021 | 90 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 351 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 146 | 0.050 |
Why?
|
| Child | 2 | 2010 | 7214 | 0.050 |
Why?
|
| Lasers | 1 | 2021 | 107 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 3053 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2020 | 223 | 0.040 |
Why?
|
| Algorithms | 2 | 2023 | 1896 | 0.040 |
Why?
|
| Patient Comfort | 1 | 2019 | 7 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 465 | 0.040 |
Why?
|
| Risk Management | 1 | 2019 | 43 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 76 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 240 | 0.040 |
Why?
|
| Hypertension | 2 | 2010 | 745 | 0.040 |
Why?
|
| Endotamponade | 1 | 2019 | 4 | 0.040 |
Why?
|
| Posture | 1 | 2019 | 124 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1463 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 192 | 0.040 |
Why?
|
| cis-trans-Isomerases | 1 | 2018 | 1 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 110 | 0.040 |
Why?
|
| Dependovirus | 1 | 2018 | 34 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2019 | 125 | 0.040 |
Why?
|
| Swine | 1 | 2019 | 588 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 120 | 0.040 |
Why?
|
| Mice | 2 | 2022 | 11828 | 0.040 |
Why?
|
| Equipment Design | 1 | 2018 | 420 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 781 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1247 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2018 | 446 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2019 | 250 | 0.030 |
Why?
|
| Pedigree | 2 | 2011 | 970 | 0.030 |
Why?
|
| Leber Congenital Amaurosis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1727 | 0.030 |
Why?
|
| Problem Solving | 1 | 2015 | 54 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 203 | 0.030 |
Why?
|
| Vision Tests | 1 | 2015 | 20 | 0.030 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 9 | 0.030 |
Why?
|
| Blindness | 1 | 2015 | 39 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 243 | 0.030 |
Why?
|
| Mutation | 1 | 2005 | 4159 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 188 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 323 | 0.030 |
Why?
|
| Aging | 1 | 1998 | 721 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 232 | 0.030 |
Why?
|
| Trabeculectomy | 1 | 2012 | 4 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2384 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 983 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 345 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2015 | 457 | 0.020 |
Why?
|
| Exotropia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Amblyopia | 1 | 2011 | 7 | 0.020 |
Why?
|
| Coloboma | 1 | 2011 | 12 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2001 | 902 | 0.020 |
Why?
|
| Propionibacterium acnes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 16 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2010 | 15 | 0.020 |
Why?
|
| Povidone-Iodine | 1 | 2010 | 9 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2004 | 1237 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2011 | 125 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2011 | 148 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2010 | 171 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 251 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3783 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2011 | 624 | 0.020 |
Why?
|
| Hospitalization | 1 | 2015 | 880 | 0.020 |
Why?
|
| Optic Disk | 2 | 1999 | 13 | 0.020 |
Why?
|
| Illinois | 1 | 2010 | 484 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 636 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 263 | 0.020 |
Why?
|
| Blood Circulation | 2 | 1998 | 30 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 139 | 0.020 |
Why?
|
| Candida | 1 | 2008 | 18 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 421 | 0.020 |
Why?
|
| Rats | 2 | 2004 | 4041 | 0.020 |
Why?
|
| Ointments | 1 | 2006 | 12 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1254 | 0.020 |
Why?
|
| Corneal Topography | 1 | 2005 | 10 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 39 | 0.020 |
Why?
|
| Consanguinity | 1 | 2005 | 73 | 0.020 |
Why?
|
| Eye Abnormalities | 1 | 2005 | 41 | 0.020 |
Why?
|
| Echinocandins | 1 | 2005 | 5 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1850 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2005 | 17 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 416 | 0.010 |
Why?
|
| Syndrome | 1 | 2005 | 449 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 529 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 453 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 210 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2063 | 0.010 |
Why?
|
| Visual Fields | 1 | 2001 | 98 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3024 | 0.010 |
Why?
|
| Sphygmomanometers | 1 | 1999 | 4 | 0.010 |
Why?
|
| Optic Nerve Diseases | 1 | 1998 | 18 | 0.010 |
Why?
|
| Blood Volume | 1 | 1998 | 49 | 0.010 |
Why?
|